Aim: Trastuzumab was first funded in New Zealand for use in HER2+ve stage I-III breast cancer in 2007. This observational study aims to ascertain the patterns of use of trastuzumab in women with invasive HER2+ve breast cancer, and assess the effectiveness of adjuvant trastuzumab in women with stage I-III HER2+ve breast cancer.
Methods: The Waikato and Auckland Breast Cancer Registries have clinical details of 12 372 women diagnosed with invasive breast cancer between June 2000 and May 2013. The proportion of women with HER2+ve breast cancer treated with trastuzumab was examined by age, ethnicity, stage and year of diagnosis. Differences in outcomes including the development of metastases and death were assessed for women with stage I-III HER2+ve breast cancer treated with both chemotherapy and trastuzumab, compared to women treated with chemotherapy alone.
Results: Among the 1587 HER2+ve breast cancer patients, 888 (56.0%) women received trastuzumab. The probability of having trastuzumab decreased with higher age and comorbidity score and increased with year of diagnosis, tumor size and cancer stage. Māori and Pacific women were less likely to be treated with trastuzumab. After adjustment for potential confounding factors, the treatment with trastuzumab improved breast cancer-specific mortality (adjusted hazard ratio 0.57, 95% CI: 0.35-0.93).
Conclusion: Overall, this observational study has shown a substantial improvement in survival for women with HER2+ve stage I-III breast cancer, and much of this improvement can be attributed to the introduction of trastuzumab. Changes in chemotherapy also appear to have led to improved outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajco.12766 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting Late Recurrence in Male Estrogen Receptor-Positive Breast Cancer With Clinical Treatment Score Post-5 years: A SEER database analysis of 65,711 cases.
Clin Breast Cancer
December 2024
Comprehensive Breast Health Center, Zhejiang Provincial Hospital of Chinese Medicine, China. Electronic address:
Purpose: Male breast cancer is an understudied disease with unique clinicopathological features. This study aims to evaluate the predictive value of the Clinical Treatment Score post-5 years (CTS5) in estimating late recurrence risk in estrogen receptor-positive (ER+) male breast cancer patients.
Methods: This retrospective study includes 65,711 ER+ early male (n = 611) and female (n = 65,100) breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database diagnosed between 2010 and 2018.
Risk reducing mastectomy in Norwegian BRCA1/2 carriers.
Eur J Surg Oncol
December 2024
Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Background: Risk reducing mastectomy (RRM) is an option for women with pathogenic germline variants in BRCA1 or BRCA2 (BRCA1/2). This study investigates and compares RRM-uptake among Norwegian BRCA1/2 carriers from 2008 to 2021, temporal trends, and incidence of breast cancer (BC) after surgery.
Methods: BRCA1/2 carriers without prior breast or ovarian cancer, tested at Oslo University Hospital between January 1st 2008 and December 31st 2021 were included in the study.
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer.
ESMO Open
January 2025
Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain. Electronic address:
Background: The infiltration of tumor-infiltrating B cells and plasma cells in early-stage breast cancer has been associated with a reduced risk of distant metastasis. However, the influence of B-cell tumor infiltration on overall patient survival remains unclear.
Materials And Methods: This study explored the relationship between an antitumor immune response, measured by a 14-gene B-cell/immunoglobulin (IGG) signature, and mortality risk in 9638 breast cancer patients across three datasets.
Novel MRI-based Hyper-Fused Radiomics for Predicting Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer.
Acad Radiol
January 2025
Imaging Center, Harbin Medical University Cancer Hospital, Haping Road No.150, Nangang District, Harbin 150081, China (Q-X.C., L-Q.Z., X-Y.W., H-X.Z., J-J.L., M-C.X., H-Y.S., Z-X.K.). Electronic address:
Rationale And Objectives: To propose a novel MRI-based hyper-fused radiomic approach to predict pathologic complete response (pCR) to neoadjuvant therapy (NAT) in breast cancer (BC).
Materials And Methods: Pretreatment dynamic contrast-enhanced (DCE) MRI and ultra-multi-b-value (UMB) diffusion-weighted imaging (DWI) data were acquired in BC patients who received NAT followed by surgery at two centers. Hyper-fused radiomic features (RFs) and conventional RFs were extracted from DCE-MRI or UMB-DWI.
Structural isomers of carene persuade apoptotic cell death by inhibiting cell cycle in breast cancer cells: An in silico and in vitro approach.
Tissue Cell
December 2024
Department of Food Science and Biotechnology, Sejong University, Gwangjin-gu, Seoul, Republic of Korea. Electronic address:
For the first time, our study provides a comprehensive examination of the anti-cancer effects of structural isomers of carene in breast cancer cells, specifically focusing on cell cycle inhibition and the induction of apoptosis. We utilized the hydro-distillation method to extract Piper nigrum seed essential oil (PNS-EO) and identified its bioactive components through gas chromatography-mass spectrometry (GC-MS) analysis. A total of 46 bioactive compounds were isolated via hydro-distillation, identified through GC-MS analysis, and validated by co-injection using GC analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!